Research ArticleHuman Studies
Phase I Radioimmunotherapy Trial with Iodine-131-CC49 in Metastatic Colon Carcinoma
C.R. Divgi, A.M. Scott, L. Dantis, P. Capitelli, K. Siler, S. Hilton, R.D. Finn, N. Kemeny, D. Kelsen, L. Kostakoglu, J. Schlom and S.M. Larson
Journal of Nuclear Medicine April 1995, 36 (4) 586-592;
C.R. Divgi
A.M. Scott
L. Dantis
P. Capitelli
K. Siler
S. Hilton
R.D. Finn
N. Kemeny
D. Kelsen
L. Kostakoglu
J. Schlom


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Phase I Radioimmunotherapy Trial with Iodine-131-CC49 in Metastatic Colon Carcinoma
C.R. Divgi, A.M. Scott, L. Dantis, P. Capitelli, K. Siler, S. Hilton, R.D. Finn, N. Kemeny, D. Kelsen, L. Kostakoglu, J. Schlom, S.M. Larson
Journal of Nuclear Medicine Apr 1995, 36 (4) 586-592;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Emerging Role of Platelet-Derived Growth Factor Receptor-{beta} Inhibition in Radioimmunotherapy of Experimental Pancreatic Cancer
- Construction, Affinity Maturation, and Biological Characterization of an Anti-tumor-associated Glycoprotein-72 Humanized Antibody
- Novel Antibody Hinge Regions for Efficient Production of CH2 Domain-deleted Antibodies
- Patient-Specific Dosimetry of Pretargeted Radioimmunotherapy Using CC49 Fusion Protein in Patients with Gastrointestinal Malignancies
- Current Status of Therapy of Solid Tumors
- A Phase I Trial of 90Y-Anti-Carcinoembryonic Antigen Chimeric T84.66 Radioimmunotherapy with 5-Fluorouracil in Patients with Metastatic Colorectal Cancer
- In Vitro Affinity Maturation of a Specificity-Determining Region-Grafted Humanized Anticarcinoma Antibody: Isolation and Characterization of Minimally Immunogenic High-Affinity Variants
- Methylxanthine Sensitization of Human Colon Cancer Cells to 186Re-Labeled Monoclonal Antibody
- Optimal Quality 131I-Monoclonal Antibodies on High-Dose Labeling in a Large Reaction Volume and Temporarily Coating the Antibody with IODO-GEN
- Single-Dose versus Fractionated Radioimmunotherapy of Human Colon Carcinoma Xenografts Using 131I-labeled Multivalent CC49 Single-chain Fvs
- High-Dose Therapy with 90Yttrium-labeled Monoclonal Antibody CC49: A Phase I Trial
- Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies
- Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only
- Hairy Cell Leukemia, a B-Cell Neoplasm That Is Particularly Sensitive to the Cytotoxic Effect of Anti-Tac(Fv)-PE38 (LMB-2)
- Responses in Refractory Hairy Cell Leukemia to a Recombinant Immunotoxin
- Radioimmunotherapy of Human Colon Cancer Xenografts Using a Dimeric Single-Chain Fv Antibody Construct